Concepedia

Peter Bruenker

PB

5

Publications

497

Citations

5

H-Index

2006

Active since

Affiliations

Roche (Switzerland)(Current)

Roche Pharma AG (Germany)

University Medical Center Groningen

University of Leicester

University of Groningen

Peter Bruenker is an author at Roche (Switzerland) specializing in tumor biology, cell transplantation, and cancer research.

Top concepts

Publications per year

2006–2021

5

Publications

5

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

Marina Bacac, Tanja Fauti, Johannes Sam et al. · Clinical Cancer Research · 2016 · 342 citations · Full text

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies

S. Jordan Kerns, Chaitra Belgur, Debora B. Petropolis et al. · eLife · 2021 · 69 citations · Full text

, , +17

Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.

Pablo Umaña, Ekkehard Moessner, Peter Bruenker et al. · Blood · 2006 · 52 citations

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.

Pablo Umaña, Ekkehard Moessner, Peter Bruenker et al. · Blood · 2007 · 22 citations

First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils

Felix Weber, Daniel Breustedt, Sonja Schlicht et al. · Pharmaceutical Research · 2018 · 12 citations · Full text

Rows per page

1–5 of 5